Join more than 165,000 subscribers and keep yourself informed with the latest financial news, insights and expert analysis to help you understand what really matters when it comes to your finances.
You are now subscribed
Your newsletter sign-up was successful
Want to add more newsletters?
An account already exists for this email address, please log in.
Gamble of the week: ground-breaking biotech stock
In five or ten years' time, this biotech outfit could be a household name, says Paul Hill, and looks a good long-term bet.
Unless you're a medical expert, you'll probably never have heard of ISIS Pharmaceuticals. But in five to ten years' time, assuming things go according to plan, this biotech outfit could be a household name. That's because it has developed a ground-breaking new technique called 'antisense'.
Many of today's most common diseases such as cardiovascular problems, cancer and diabetes are caused by 'bad' proteins being wrongly produced in the human body. Current drugs attack these dangerous cells, but the problem is that the side effects can be extreme, and the efficacy poor.
In contrast, antisense operates one step ahead in the DNA chain. It stops these disease-causing proteins from ever being generated by turning off the genes that encode the protein. This means none of the 'good' cells are harmed, so the side effects are far fewer, and the treatment can be tailored to each individual patient.
Try 6 free issues of MoneyWeek today
Get unparalleled financial insight, analysis and expert opinion you can profit from.
Sign up for MoneyWeek’s free twice-daily newsletter.
Join more than 165,000 subscribers and keep yourself informed with latest financial news, insights and expert analysis to help you understand what really matters when it comes to your finances.
Join more than 165,000 subscribers and keep yourself informed with latest financial news, insights and expert analysis to help you understand what really matters when it comes to your finances.
ISIS owns 1,600 patents and currently has 19 drugs in the pipeline, most of which are being jointly developed with partners such as Genzyme, Bristol-Myers Squibb and Novartis.
ISIS's first potential blockbuster drug is Mipomersen, which is aimed at cutting cholesterol levels. It's presently undergoing Phase III clinical trials; submission to the US regulator, the FDA, is set for 2010. So far the results have been very encouraging. The chief executive said in August that "key opinion leaders with whom we have shared the detailed data are thrilled".
Assuming he's right, and the FDA approves Mipomersen in 2011, shares could rocket overnight. A positive verdict would not only give the green light to this specific treatment, but would more importantly provide a huge endorsement to the whole antisense drug class. There's also no danger of patent expiries until 2023 at the earliest, and the group has $500m in net cash (or $5 a share) to fund itself for the foreseeable future.
What are the potential pitfalls? As with most early-stage biotechs, ISIS is still loss making and its success depends on one main therapeutic area. But with antisense being such a breakthrough, ISIS looks a good bet on the long-term growth in personalised medicine and ageing populations, along with being a takeover target for Big Pharma.
Recommendation: speculative BUY at $14.50 (market capitalisation $1.4bn)
Paul Hill also writes a weekly share-tipping newsletter, Precision Guided Investments
Sign up for MoneyWeek's newsletters
Join more than 165,000 subscribers and keep yourself informed with the latest financial news, insights and expert analysis to help you understand what really matters when it comes to your finances.
Paul gained a degree in electrical engineering and went on to qualify as a chartered management accountant. He has extensive corporate finance and investment experience and is a member of the Securities Institute.
Over the past 16 years Paul has held top-level financial management and M&A roles for blue-chip companies such as O2, GKN and Unilever. He is now director of his own capital investment and consultancy firm, PMH Capital Limited.
Paul is an expert at analysing companies in new, fast-growing markets, and is an extremely shrewd stock-picker.
